Targeting Legumain As a Novel Therapeutic Strategy in Cancers

摘要

背景：最近的报告表明，肿瘤微环境在癌症发展和进展中起关键作用，导致癌症研究和靶向的范式转变。与传统的方法相反，只有肿瘤细胞被靶向治疗，新兴的方法是开发靶向肿瘤微环境的治疗剂，同时补充或增强目前的治疗。 Legumain（LGMN）是一种新鉴定的靶点，在肿瘤微环境和肿瘤细胞中高度表达，具有生物标志物和治疗靶点的潜力。结论：本综述将首先总结LGMN在常见癌症中的表达及其在肿瘤发生和转移中的作用。该评论还通过开发DNA疫苗，azopeptides，小分子抑制剂和LGMN活化前药来讨论目标LGMN的发展和未来前景，突出了LGMN作为癌症治疗靶标的潜力。

关键词: Legumain，癌症，肿瘤微环境，疫苗，偶氮肽，小分子，前药。

« Previous Next »

图形摘要

Rights & Permissions Print Cite

Current Drug Targets

Title:Targeting Legumain As a Novel Therapeutic Strategy in Cancers

Volume: 18 Issue: 11

关键词: Legumain，癌症，肿瘤微环境，疫苗，偶氮肽，小分子，前药。

摘要: Background: Recent reports indicate that the tumor microenvironment plays a pivotal role in cancer development and progression, leading to a paradigm shift in the way cancer is studied and targeted. In contrast to traditional approaches, where only tumor cells are targeted for the treatment, an emerging approach is to develop therapeutics which target the tumor microenvironment while complementing or enhancing current treatments. Legumain (LGMN) is a newly identified target which is highly expressed in the tumor microenvironment and in tumor cells, and holds potential both as a biomarker and as a therapeutic target.

Conclusion: This review will be the first to summarize the expression of LGMN in common cancers, as well as its roles in tumorigenesis and metastasis. This review also discusses the current developments and future prospects of targeting LGMN through the development of DNA vaccines, azopeptides, small molecule inhibitors and LGMN activated prodrugs, highlighting the potential of LGMN as a target for cancer therapeutics.

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Targeting Legumain As a Novel Therapeutic Strategy in Cancers, Current Drug Targets 2017; 18 (11) . https://dx.doi.org/10.2174/1389450117666161216125344

DOI https://dx.doi.org/10.2174/1389450117666161216125344	Print ISSN 1389-4501
Publisher Name Bentham Science Publisher	Online ISSN 1873-5592

About this journal

Call for Papers in Thematic Issues

Submission closes on : 09 June, 2024

New drug therapy for eye diseases

Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more

Guest Editor(s): Dr. Yalong Dang